chr11-47332244-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000256.3(MYBPC3):c.3642G>A(p.Trp1214Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000124 in 1,613,680 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000256.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.3642G>A | p.Trp1214Ter | stop_gained | 33/35 | ENST00000545968.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.3642G>A | p.Trp1214Ter | stop_gained | 33/35 | 5 | NM_000256.3 | P4 | |
MYBPC3 | ENST00000399249.6 | c.3642G>A | p.Trp1214Ter | stop_gained | 32/34 | 5 | A2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152220Hom.: 0 Cov.: 33
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461460Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 727036
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152220Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74374
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 26, 2017 | The W1214X variant in the MYBPC3 gene has been reported in an Indian male patient with familial HCM who also harbored another variant in the MYH7 gene (Bashyam M et al., 2012). The variant was absent from 100 ethnically matched control individuals. W1214X is predicted to cause loss of normal protein function either by protein truncation or nonsense mediated mRNA decay. Other nonsense variants in the MYBPC3 gene have been reported in association with HCM. In summary, W1214X in the MYBPC3 gene is interpreted as a disease-causing variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2023 | MYBPC3: PVS1, PM2, PS4:Moderate - |
Hypertrophic cardiomyopathy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 01, 2023 | This sequence change creates a premature translational stop signal (p.Trp1214*) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is present in population databases (rs368765949, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 21959974, 24093860). ClinVar contains an entry for this variant (Variation ID: 162506). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Hypertrophic cardiomyopathy 4;C3715165:Left ventricular noncompaction 10 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Sep 16, 2021 | - - |
Cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Aug 20, 2019 | This variant changes 1 nucleotide in exon 33 of the MYBPC3 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. A different variant (c.3641G>A) resulting in the same protein effect (p.Trp1214*) has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 21959974, 24093860). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MYBPC3 function is a known mechanism of disease. Based on the available evidence, this variant is classified as Pathogenic. - |
Primary dilated cardiomyopathy;C4021133:Left ventricular noncompaction cardiomyopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Petrovsky National Research Centre of Surgery, The Federal Agency for Scientific Organizations | Oct 15, 2020 | We observed a c.3642G>A (p.W1214*) genetic variant in a 30-y.o. female proband, diagnosed with non-compaction cardiomyopathy, dilatation of cardiac chambers and heart rhythm disturbances. The proband also carried the additional variant of unknown clinical significance in MYBPC3 gene - p.P186L in heterozygous state. The family was unavailable for screening. The p.W1214* genetic variant is a nonsense mutation in the MYBPC3 gene. No functional studies are available for the p.W1214* variant, however, nonsense variants in MYBPC3 gene are well-known to cause cardiomyopathy through haploinsufficiency. According to Cardio Classifier predictions, mRNA carrying the p.W1214* variant, will be processed through nonsence-mediated decay mechanism, leading to haploinsufficiency. We assume that the p.W1214* variant could be classified as likely pathogenic. - |
Hypertrophic cardiomyopathy 4 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Genetics and Molecular Cardiology, University of São Paulo | - | - - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 02, 2020 | The p.W1214* pathogenic mutation (also known as c.3642G>A), located in coding exon 33 of the MYBPC3 gene, results from a G to A substitution at nucleotide position 3642. This changes the amino acid from a tryptophan to a stop codon within coding exon 33. This mutation has been reported in hypertrophic cardiomyopathy (HCM) cohorts, including one HCM case with an additional MYH7 variant also detected (Bashyam MD et al. Mol. Cell. Biochem., 2012 Jan;360:373-82; Marsiglia JD et al. Am. Heart J., 2013 Oct;166:775-82; Kapplinger JD et al. J Cardiovasc Transl Res, 2014 Apr;7:347-61; Ingles J et al. Circ Cardiovasc Genet, 2017 Apr;10:[Epub ahead of print]). This variant has also been seen in an exome cohort, but cardiovascular history was not provided (Andreasen C et al. Eur. J. Hum. Genet., 2013 Sep;21:918-28; Amendola LM et al. Genome Res., 2015 Mar;25:305-15). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
MYBPC3-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 11, 2024 | The MYBPC3 c.3642G>A variant is predicted to result in premature protein termination (p.Trp1214*). This variant has been reported in individuals with autosomal dominant hypertrophic cardiomyopathy (Marsiglia et al. 2013. PubMed ID: 24093860; Table S1 in Helms et al. 2020. PubMed ID: 32841044; Table S2 in Burstein et al. 2021. PubMed ID: 32746448). This variant has not been reported in a large population database, indicating this variant is rare. Nonsense variants in MYBPC3 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at